North America In Vitro Diagnostics (IVD) Quality Control Market | Bussiness Insights
Press Releases
North America In Vitro Diagnostics (IVD) Quality Control Market - Market Share Analysis, Industry Trends & Statistics, and Growth Forecasts 2020 - 2035
The North America In Vitro Diagnostics (IVD) Quality Control Market is experiencing substantial growth, driven by technological advancements and increasing healthcare expenditure. The market size was valued at USD 1,350 Million in 2025 and is projected to reach USD 2,720 Million by 2035, growing at a CAGR of 6.5% from 2024 to 2035.
The economic impact of tariffs on "North America In Vitro Diagnostics (IVD) Quality Control Market".
Market Growth Drivers
Rising Demand for Accurate Diagnostic Results: The growing emphasis on delivering rapid and precise diagnostic results for a range of diseases, such as infectious diseases and cancer, is significantly boosting the adoption of quality control solutions in laboratories. Companies like Bio-Rad Laboratories have launched comprehensive QC solutions that support clinical labs in achieving regulatory compliance while ensuring accurate results. This rising demand is further supported by increased awareness among healthcare professionals and the higher incidence of chronic diseases requiring constant monitoring and diagnostics.
Technological Advancements in IVD Platforms: Continuous innovation in molecular diagnostics and immunoassays is enhancing the capabilities of IVD QC products. Major players such as Thermo Fisher Scientific have introduced next-generation QC materials integrated with digital tools for monitoring and data interpretation, making quality control more robust and efficient. These technological upgrades are attracting both public and private diagnostic settings, thereby driving robust market growth across North America.
Market Trends
Integration of Artificial Intelligence and Data Analytics: There is an increasing trend towards leveraging artificial intelligence (AI) and advanced data analytics to improve quality control in IVD. Companies like Siemens Healthineers have developed smart QC management platforms that utilize AI to predict instrument downtime and streamline operations, enhancing overall efficiency. This integration is aiding in proactive decision-making and optimization of laboratory workflows.
Adoption of Cloud-Based Quality Control Systems: Cloud-enabled QC management solutions are gaining traction for their ability to offer real-time data storage, remote accessibility, and multi-site standardization. Roche Diagnostics has been a leading player in rolling out cloud-based QC systems that allow laboratories to track, analyze, and share QC data seamlessly. This trend is helping labs maintain compliance, particularly in multi-location and reference laboratory networks across North America.
Market Opportunity
Expansion into Point-of-Care (POC) Testing: The surge in demand for point-of-care testing devices across decentralized settings, including home care and outpatient facilities, presents a significant opportunity. Companies such as Abbott are enhancing their quality control offerings for POC devices to ensure reliable results, paving the way for broader market penetration.
Growth in Companion Diagnostics: The rise in personalized medicine and companion diagnostics is opening new avenues for specialized QC products. Firms like Danaher are investing in QC solutions tailored to companion diagnostics, supporting the growth and diversification of the IVD QC market in North America.
North America IVD Quality Control Market Revenue (USD Million), 2020-2035
The market revenue for the North American IVD Quality Control sector shows a clear upward trajectory from 2020 to 2035. Starting at USD 850 Million in 2020, the market grows steadily, reaching USD 1,200 Million in 2023, USD 1,350 Million in 2025, and is forecasted to reach USD 2,720 Million by 2035. This sustained growth reflects ongoing investments in laboratory infrastructure, rising regulatory standards, and greater adoption of advanced diagnostic technologies. Key inflection points include the post-pandemic acceleration in lab automation and the expansion of molecular diagnostic applications.
North America IVD Quality Control Market Share by Region, 2025
In 2025, the United States dominates the North America IVD Quality Control market with a 78% share, driven by its highly advanced healthcare infrastructure and high diagnostic testing volumes. Canada follows with 15%, reflecting its rising investments in healthcare modernization. Mexico accounts for 5% as it gradually upgrades its diagnostic capabilities. The remaining 2% is distributed among other regions in North America, including Bermuda and the Caribbean. This regional distribution highlights the strategic significance of the U.S. market for industry leaders while indicating potential growth opportunities in Canada and Mexico.
Recent Developments
In February 2024, Bio-Rad Laboratories announced the launch of the Unity Next QC Peer Group program in the U.S. and Canada, enabling clinical laboratories to compare performance data across thousands of labs in real time. This innovation helps labs optimize their processes, meet compliance standards, and further raises the industry benchmark for quality control.
In March 2024, Thermo Fisher Scientific acquired a controlling stake in a start-up specializing in cloud-connected QC software for molecular diagnostics, integrating digital workflows for real-time analytics and quality assurance. This strategic move has broadened Thermo Fisher's digital health portfolio and enhanced their offering for centralized and decentralized lab networks.
In April 2024, Roche Diagnostics expanded its partnership with several U.S. academic medical centers to pilot an AI-based QC platform that provides predictive monitoring of IVD instrument performance. The initiative, set to roll out in major U.S. cities, demonstrates industry leadership in the fusion of data-driven technologies and diagnostics quality.
Press Releases